Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

P&G/Aventis Actonel Is Priced At 10% Discount To Merck Fosamax

  • News

Executive Summary

Procter & Gamble and marketing partner Aventis will set the price of its Actonel dose for osteoporosis at a discount to Merck's Fosamax.

You may also be interested in...



Merck Fosamax 40 mg Distribution Plan Leaves Room For Once-Weekly Agent

Merck's exclusive distribution program for patients receiving Fosamax 40 mg tablets for Paget's disease will give the company pricing flexibility when a once-weekly 35 mg formulation is approved for prevention of osteoporosis.

Merck Fosamax 40 mg Distribution Plan Leaves Room For Once-Weekly Agent

Merck's exclusive distribution program for patients receiving Fosamax 40 mg tablets for Paget's disease will give the company pricing flexibility when a once-weekly 35 mg formulation is approved for prevention of osteoporosis.

Merck Zocor U.S. Sales Headed Past $3 Bil.: Company Sees 20% Growth

U.S. sales of Zocor appear on track to top $3 bil. in 2000 based on projections of 20% growth for the full year.

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS035935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By